Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

As part of the license agreement with Novo, Deep Apple will be eligible to receive up to $812 million in payments, as well as ...

Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Wegovy maker Novo Nordisk has hired the start-up Deep Apple Therapeutics to develop small molecules as its next weight-loss ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

Novo Nordisk has launched a late-stage trial for its obesity drug candidate, CagriSema, aiming to restore market confidence ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...